Immunotherapy | Surviving Mesothelioma

MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma

Australian scientists say it may be possible to artificially reduce the levels of a protein that helps mesothelioma tumors hide from the immune system. The new research published in the Journal of Thoracic Oncology could open the door to more effective immunotherapy treatments for pleural mesothelioma. The Importance of PD-L1 Expression A cell surface protein called PD-L1 is key to the effectiveness of several new … Continue reading MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma »

Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma

Viruses may soon be playing a bigger role in the fight against malignant mesothelioma and other thoracic cancers. A pair of biologists from Minnesota say there is evidence that, in addition to killing mesothelioma cells directly, specific kinds of altered viruses might help make mesothelioma immunotherapy treatment more effective. How Does Immunotherapy Work? Like many other types of cancer, mesothelioma tumors are able to grow unchecked … Continue reading Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma »

Immunotherapy and Radiation: A Powerful Mesothelioma Combo

New research suggests that, in the battle against malignant pleural mesothelioma, a treatment combining of immunotherapy drugs with radiotherapy may be a powerful new weapon. Researchers at the University of Pennsylvania reached that conclusion after reviewing the few existing studies on this emerging multimodal mesothelioma treatment for an article in Translational Lung Cancer Research.   Current available treatments for pleural mesothelioma, an aggressive lung-related cancer,  include surgical resection, … Continue reading Immunotherapy and Radiation: A Powerful Mesothelioma Combo »

MS Drug May Help Treat Malignant Mesothelioma, Too

Preliminary tests of a potential new mesothelioma treatment have yielded some exciting results at the University of Hawaii Cancer Center. Mesothelioma researchers there are evaluating an immune system modulator called FTY720 or fingolimod. Derived from a fungus called Iscaria sinclairii, FTY720 has been used to treat the relapsing form of multiple sclerosis. Although FTY720 has shown what the research team calls “therapeutic potential” in some … Continue reading MS Drug May Help Treat Malignant Mesothelioma, Too »

The Key to Mesothelioma Treatment Success with Immunotherapy

Researchers with a biotechnology company that makes antibody-drug conjugates (ADC) for hard-to-treat cancers like malignant mesothelioma say careful patient selection is the key to treatment success. Writing in the journal Advances in Therapy, John Lambert and Charles Morris of Massachusetts-based ImmunoGen call for the development of a “patient selection strategy” so that more mesothelioma patients and those with other cancers can take advantage of the … Continue reading The Key to Mesothelioma Treatment Success with Immunotherapy »

Immunotherapy for Pleural Mesothelioma: Does it Work?

Immunotherapy is an important emerging therapeutic strategy for several types of cancer, but the jury is still out on whether it will eventually be a viable approach for malignant pleural mesothelioma. In a newly-published special report on the immune checkpoint inhibitor tremelimumab, researchers at the University of Salford in the UK call the use of such drugs “largely questionable” for pleural mesothelioma treatment. Their concerns, … Continue reading Immunotherapy for Pleural Mesothelioma: Does it Work? »

Immunotherapy Drug May Be New Option for Recurrent Mesothelioma

There may be new hope for malignant mesothelioma patients whose cancer recurs after treatment. A presentation at the recent World Lung Cancer conference in Vienna earlier this month suggests that the immunotherapy drug nivolumab (brand name Opdivo) could help people with pleural mesothelioma who have run out of treatment options. The author of the new study says his Amsterdam-based team has recorded mesothelioma survival of … Continue reading Immunotherapy Drug May Be New Option for Recurrent Mesothelioma »

New Mesothelioma Immunotherapies Target Key Protein

The cell-surface glycoprotein mesothelin is poised to be a key part of several new immunotherapy approaches for the treatment of malignant pleural mesothelioma, a treatment-resistant cancer caused by asbestos. A team of top mesothelioma researchers with the National Cancer Institute’s Center for Cancer Research recently published their analysis of several ongoing studies of therapies that target mesothelin in mesothelioma treatment. Mesothelin’s Relationship to Mesothelioma Mesothelin is … Continue reading New Mesothelioma Immunotherapies Target Key Protein »

Mesothelioma Treatment News: Novel Immunotherapy Drug Featured at International Symposium

A promising immunotherapy drug made from a deactivated cold virus has cleared another hurdle on its way to becoming a viable new treatment for malignant mesothelioma. Scientists with the Norway-based company that makes ONCOS-102 presented their most recent mesothelioma research data to colleagues at a symposium hosted by the International Society of Stem Cell Research and the European Society of Gene and Cell Therapy in October. … Continue reading Mesothelioma Treatment News: Novel Immunotherapy Drug Featured at International Symposium »

Maine Man Defies the Odds by Forging His Own Mesothelioma Treatment Path

When Jim McHutchison, an otherwise healthy 72-year-old from York, Maine, developed a cough and shortness of breath in the Fall of 2012, neither he nor his doctors had reason to suspect it was pleural mesothelioma.  “I never worked near asbestos in a shipyard or around heavy construction. I’m an advertising guy. I work in an office,” McHutchison told Surviving Mesothelioma. Noting that Jim had fluid … Continue reading Maine Man Defies the Odds by Forging His Own Mesothelioma Treatment Path »

Get your free copy of
“Surviving Mesothelioma” Today!